Riskpilot← Back to searchSign inGet full accessENDORFIN BEHANDLINGSKLINIKK AS
ASIn liquidationOrg 915549020Dronning Ragnas Gate 14, 4010 StavangerOther human health activities n.e.c. · NACE 8699Est. 20151 employeeswww.endorfin.no
Revenue 2024
NOK 719K
+14% vs 2023
EBITDA margin
5.3%
+201% vs 2023
Equity ratio
-158.8%
Financial strength
Net profit 2024
NOK 38K
+186% vs 2023
| Revenue | NOK 719K | +14% |
| EBITDA | NOK 38K | +201% |
| Net profit | NOK 38K | +186% |
| Total assets | NOK 55K | +16% |
| Equity | NOK -88K | +30% |
| Employees | 1 | — |
Legal name
ENDORFIN BEHANDLINGSKLINIKK AS
Org number
915549020
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
24. juni 2015
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Styrets leder alene.
Company purpose
Massasjeterapi og yoga, og annet som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet.
Address
Dronning Ragnas Gate 14, 4010 Stavanger
Website
www.endorfin.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 229 | 208 | 425 | 605 | 335 | 486 | 11 | 532 | 632 | 719 |
| Staff expenses | −224 | −173 | −215 | −396 | −213 | −296 | −25 | −378 | −536 | −535 |
| EBITDA | −42 | −83 | 62 | 58 | −19 | 36 | −90 | −40 | −37 | 38 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −42 | −83 | 62 | 58 | −19 | 36 | −90 | −40 | −37 | 38 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 |
| Profit before tax | −42 | −83 | 62 | 58 | −19 | 36 | −90 | −40 | −39 | 38 |
| Tax | −11 | −20 | 16 | 13 | −4 | −0 | −0 | −0 | 5 | −0 |
| Net profit | −32 | −64 | 47 | 44 | −15 | 36 | −90 | −40 | −44 | 38 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 50 | 14 | 76 | 98 | 49 | 96 | 40 | 38 | 48 | 55 |
| Equity | −2 | −65 | −19 | 26 | 11 | 47 | −41 | −81 | −126 | −88 |
| Long-term debt | 0 | 44 | 29 | 0 | 9 | 9 | 9 | 9 | 9 | 9 |
| Short-term debt | 51 | 36 | 65 | 72 | 29 | 40 | 73 | 111 | 164 | 134 |
| Total debt | 51 | 80 | 95 | 72 | 38 | 49 | 82 | 119 | 173 | 143 |
EBITDA margin
5.3%
This company
15.8%
Market median
-66% vs market
20152024
Equity ratio
-158.8%
This company
38.2%
Market median
-516% vs market
20152024
Return on equity
3782100.0%
This company
18.4%
Market median
+20554791% vs market
20152024
Net profit margin
5.3%
This company
8.1%
Market median
-35% vs market
20152024
Asset turnover
13.01×
This company
1.12×
Market median
+1062% vs market
20152024
Debt / equity
1.63×
This company
0.62×
Market median
-163% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TS Deputy Member | Deputy Member | 2015 | — | — |
SF Accountant | Accountant | 2015 | — | — |
KV Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ENDORFIN BEHANDLINGSKLINIKK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Skavland | Deputy Member | 0 companies |
| Sigbjørn Førre | Accountant | 0 companies |
| Karoline Vågane Skavland | Chief Executive Officer | 0 companies |